Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 2/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | ICMT | O60725 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2867777 | 1.00 | LSS (0.40) | LSSFNTAFNTBTSHRMAPT | |
| SCHEMBL29319606 | 0.83 | HTT (0.36) | LSSMAPTHTTFAAH | |
| SCHEMBL10000151 | 0.81 | TSHR (0.42) | LSSFNTAFNTBTSHRMAPT | |
| SCHEMBL19850432 | 0.79 | FNTA (0.46) | LSSFNTAFNTBTSHRMAPT | |
| SCHEMBL2865999 | 0.79 | GPR174 (0.40) | L3MBTL1 | |
| SCHEMBL2865998 | 0.79 | GPR174 (0.40) | L3MBTL1 | |
| SCHEMBL2870332 | 0.78 | LSS (0.49) | LSSFNTAFNTBTSHRALDH1A1 | |
| SCHEMBL10000088 | 0.78 | LSS (0.46) | LSSFNTAFNTBTSHRMAPT | |
| SCHEMBL2870331 | 0.78 | LSS (0.49) | LSSFNTAFNTBTSHRALDH1A1 | |
| SCHEMBL10000083 | 0.77 | LSS (0.43) | LSSFNTAFNTBTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728180-B2 | Method for producing ethers | KURARAY CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080262272-A1 | Method For Producing Ethers | KURARAY CO., LTD. (JP) | 2008-10-23 | — | — | US | disclosed |
| CN-1972888-A | Method for producing ethers | KURARAY CO (JP) | 2007-05-30 | — | — | CN | disclosed |
| EP-1760061-A1 | METHOD FOR PRODUCING ETHERS | KURARAY CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262272-A1 | Method For Producing Ethers | TELO2, PDS5A, TERT | LSS 1302/4885FNTA 4026/4885FNTB 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.